Leading causes of death in alcoholic ARDS patients using clinical data
Official title: Identification of leading causes and paths of death in alcoholic ARDS patients through clinical dataset-wide computations
Funded at Loyola University Chicago · NIH-11442761 · Data updated 2026-11-12
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Loyola University Chicago NIH-funded |
| Lab location | 1 site (Maywood, United States) |
| Project start | August 17, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $115,500 |
| NIH project number | 1R21AA033945-01 |
| Project ID | NIH-11442761 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with acute respiratory distress syndrome who have a history of alcohol use/misuse and are eligible for the included clinical trial cohorts.
✕Less likely to help
Patients without alcohol misuse or ARDS may not benefit from the findings specific to alcoholic ARDS.
What this research studies
In this project, researchers will analyze large sets of clinical data from ARDS patients, focusing on those with alcohol misuse, to identify key factors linked to mortality. They will combine machine learning with causal modeling to surface the most important predictors of death and how they interact. The study will validate these findings in a larger, independent cohort drawn from five NIH-funded clinical trials, ensuring results are robust across diverse populations. The ultimate goal is to clarify which medical factors matter most so clinicians can target interventions for alcoholic ARDS patients.
Why it matters
Potential benefit: Patients with alcoholic ARDS could see more personalized risk information and targeted care strategies that address the most important drivers of mortality.
How similar studies have gone: Preliminary analyses in ARDS cohorts using ML and causal methods have shown promise in identifying mortality-related factors, with broader validation ongoing.
Where this research is happening
-
Loyola University Chicago
Maywood, United States Active
Researchers
- Principal investigator: Ji, Hong-Long — Loyola University Chicago
- Study coordinator: Ji, Hong-Long
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
-
Innovative immune therapy with antibiotics to treat deadly inflammation in sepsis and ARDS in older adults
A new approach combines an antibiotic strategy with a special immune-based treatment to help older patients who have sepsis or ARDS from severe bacterial infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.